Browsing Tag
Tirzepatide
30 posts
Eli Lilly’s tirzepatide shows promising results for obstructive sleep apnea in latest clinical trials
Eli Lilly and Company (NYSE: LLY) has announced promising results from the SURMOUNT-OSA phase 3 clinical trials of…
Eli Lilly’s tirzepatide shows promising results in MASH treatment study
Eli Lilly and Company (NYSE: LLY) revealed compelling outcomes from the SYNERGY-NASH study, showcasing significant efficacy of tirzepatide…
Lilly announces significant results in SURMOUNT-OSA trials of tirzepatide in OSA
Eli Lilly and Company (NYSE: LLY) has released positive topline results from the phase 3 SURMOUNT-OSA clinical trials,…
Lilly’s Zepbound marks remarkable weight loss milestone in SURMOUNT-4 study
In a significant development in the field of obesity treatment, Lilly’s Zepbound (tirzepatide) has shown remarkable results in…
Lilly bags Zepbound FDA approval for obesity treatment
The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Zepbound (tirzepatide) injection, making it the…
Lilly expands portfolio with $1.9bn acquisition of Versanis Bio
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully…
Eli Lilly Q2 2023 financial results highlight robust 28% revenue growth
Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven…
Eli Lilly’s Tirzepatide triumphs in Phase 3 weight loss studies
Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting…
Lilly’s tirzepatide shows superior weight reduction in phase 3 trial
Eli Lilly and Company (Lilly) said that tirzepatide has shown superior efficacy over placebo in chronic weight management,…
Lilly gets FDA fast track designation for tirzepatide in obesity
Eli Lilly and Company (Lilly) has been granted fast track designation for tirzepatide from the US Food and…